Abstract
This article explores the feasibility and potential benefits of stem cell therapy as a promising therapeutic intervention for individuals facing severe behavioral and cognitive impairments, targeting underlying neurological mechanisms to offer potential symptom improvement and function restoration, thereby enhancing the quality of life for patients and potentially alleviating stress and burnout among caregivers. The aims of the study include investigating the efficacy of stem cell therapy in addressing these impairments and evaluating its potential to alleviate caregiver burden. Through a comprehensive review of existing literature, clinical trials, and studies, this research synthesizes the mechanisms of stem cell therapy, potential applications, clinical trial outcomes, caregiver experiences, and economic implications. The methods employed involve analyzing diverse data sources to provide a holistic understanding of the possibilities and challenges associated with stem cell therapy. Key outcomes of the study include highlighting promising results from clinical trials targeting conditions such as autism spectrum disorder, Parkinson's disease, and Crohn's disease, which underscore the transformative potential of stem cell therapy in patient care. Additionally, economic implications suggest potential reductions in healthcare costs and alleviation of financial strain on individuals, families, and healthcare providers. Stem cell therapy represents a paradigm shift in healthcare, promising to redefine treatment approaches and alleviate broader societal burdens associated with complex neurological conditions. The relevance of the study lies in emphasizing the need for continued research, ethical considerations, and multidisciplinary collaboration to ensure the safe and effective integration of stem cell therapy into clinical practice, ultimately offering new hope and improved care for patients, caregivers, and healthcare systems worldwide.
Reference31 articles.
1. M. J. Maenner et al., “Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020,” MMWR. Surveillance Summaries, vol. 72, no. 2, 2023, doi: 10.15585/MMWR.SS7202A1.
2. D. K. Simon, C. M. Tanner, and P. Brundin, “Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology,” Clin Geriatr Med, vol. 36, no. 1, pp. 1–12, Feb. 2020, doi: 10.1016/j.cger.2019.08.002.
3. N. Sharifzadeh et al., “Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial,” Asia-Pacific Psychiatry, vol. 13, no. 2, p. e12445, Jun. 2021, doi: 10.1111/APPY.12445.
4. A. K. Sharma et al., “Cell transplantation as a novel therapeutic strategy for autism spectrum disorders: a clinical study,” Am J Stem Cells, vol. 9, no. 5, p. 89, 2020.
5. D. Siniscalco, S. Kannan, N. Semprún-Hernández, A. A. Eshraghi, A. L. Brigida, and N. Antonucci, “Stem cell therapy in autism: recent insights,” Stem Cells Cloning, vol. 11, pp. 55–67, Oct. 2018, doi: 10.2147/SCCAA.S155410.